Selected research
Industry Research
High Affinity Nerve Growth Factor Receptor Industry Research Report 2026
Market perspective
The global High Affinity Nerve Growth Factor Receptor market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
North America: the High Affinity Nerve Growth Factor Receptor market is projected to increase from US$ million in 2026 to US$ million by 2032, reflecting a CAGR of % over 2026–2032. Europe: the High Affinity Nerve Growth Factor Receptor market is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032. Asia Pacific: the High Affinity Nerve Growth Factor Receptor market is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032. Leading global service providers of High Affinity Nerve Growth Factor Receptor include Merck & Co Inc, AstraZeneca Plc, Tiziana Life Sciences Plc, Sienna Biopharmaceuticals Inc, Rottapharm Biotech Srl, Proximagen Ltd, Plexxikon Inc, Nerviano Medical Sciences Srl and Loxo Oncology Inc, among others; in 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
Read the full market overview
This report quantifies the global High Affinity Nerve Growth Factor Receptor market in terms of revenue (US$ million) and, where applicable, service volume (K Units), using 2024 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of service Types and end-use Applications, harmonizes provider attribution, and delivers comparable time series by company, Type, Application, and region or country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10). Outputs are intended to support service design, budgeting, capacity planning, and benchmarking for providers, platforms, channel partners, and investors; the report also reviews technology shifts and notable service innovations relevant to High Affinity Nerve Growth Factor Receptor.
Key Companies & Market Share Insights
This section profiles leading service providers with 2021–2025 results and a 2026–2032 outlook—covering revenue, market share, price bands, service portfolio and client mix, regional and channel mix, and key developments (M&A, network expansion, certifications). It also provides global revenue, average price, and—where applicable—volume metrics by provider, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
High Affinity Nerve Growth Factor Receptor Market by Company
Merck & Co Inc
AstraZeneca Plc
Tiziana Life Sciences Plc
Sienna Biopharmaceuticals Inc
Rottapharm Biotech Srl
Proximagen Ltd
Plexxikon Inc
Nerviano Medical Sciences Srl
Loxo Oncology Inc
Ignyta Inc
Handok Inc
Genzyme Corp
Dompe Farmaceutici SpA
Daiichi Sankyo Co Ltd
Astellas Pharma Inc
Array BioPharma Inc
High Affinity Nerve Growth Factor Receptor Segment by Type
Cenegermin
CRB-0089
BNN-27
AZD-7451
ASP-7962
Others
High Affinity Nerve Growth Factor Receptor Segment by Application
Low Back Pain
Papillary Thyroid Cancer
Lung Cancer
Bile Duct Cancer
Others
High Affinity Nerve Growth Factor Receptor Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Spain
Russia
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Colombia
Middle East & Africa
Saudi Arabia
Israel
United Arab Emirates
Turkey
Iran
Egypt
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global High Affinity Nerve Growth Factor Receptor market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of High Affinity Nerve Growth Factor Receptor and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of High Affinity Nerve Growth Factor Receptor.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of High Affinity Nerve Growth Factor Receptor companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Cenegermin
- CRB-0089
- BNN-27
- AZD-7451
- ASP-7962
- Others
Applications
- Low Back Pain
- Papillary Thyroid Cancer
- Lung Cancer
- Bile Duct Cancer
- Others
Companies covered
- Merck & Co Inc
- AstraZeneca Plc
- Tiziana Life Sciences Plc
- Sienna Biopharmaceuticals Inc
- Rottapharm Biotech Srl
- Proximagen Ltd
- Plexxikon Inc
- Nerviano Medical Sciences Srl
- Loxo Oncology Inc
- Ignyta Inc
- Handok Inc
- Genzyme Corp
- Dompe Farmaceutici SpA
- Daiichi Sankyo Co Ltd
- Astellas Pharma Inc
- Array BioPharma Inc
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 High Affinity Nerve Growth Factor Receptor by Type
- 2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032)
- 2.2.2 Cenegermin
- 2.2.3 CRB-0089
- 2.2.4 BNN-27
- 2.2.5 AZD-7451
- 2.2.6 ASP-7962
- 2.2.7 Others
- 2.3 High Affinity Nerve Growth Factor Receptor by Application
- 2.3.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.3.2 Low Back Pain
- 2.3.3 Papillary Thyroid Cancer
- 2.3.4 Lung Cancer
- 2.3.5 Bile Duct Cancer
- 2.3.6 Others
- 2.4 Assumptions and Limitations
3 High Affinity Nerve Growth Factor Receptor Breakdown Data by Type
- 3.1 Global High Affinity Nerve Growth Factor Receptor Historic Market Size by Type (2021-2026)
- 3.2 Global High Affinity Nerve Growth Factor Receptor Forecasted Market Size by Type (2027-2032)
4 High Affinity Nerve Growth Factor Receptor Breakdown Data by Application
- 4.1 Global High Affinity Nerve Growth Factor Receptor Historic Market Size by Application (2021-2026)
- 4.2 Global High Affinity Nerve Growth Factor Receptor Forecasted Market Size by Application (2027-2032)
5 Global Growth Trends
- 5.1 Global High Affinity Nerve Growth Factor Receptor Market Perspective (2021-2032)
- 5.2 Global High Affinity Nerve Growth Factor Receptor Growth Trends by Region
- 5.2.1 Global High Affinity Nerve Growth Factor Receptor Market Size by Region: 2021 VS 2025 VS 2032
- 5.2.2 High Affinity Nerve Growth Factor Receptor Historic Market Size by Region (2021-2026)
- 5.2.3 High Affinity Nerve Growth Factor Receptor Forecasted Market Size by Region (2027-2032)
- 5.3 High Affinity Nerve Growth Factor Receptor Market Dynamics
- 5.3.1 High Affinity Nerve Growth Factor Receptor Industry Trends
- 5.3.2 High Affinity Nerve Growth Factor Receptor Market Drivers
- 5.3.3 High Affinity Nerve Growth Factor Receptor Market Challenges
- 5.3.4 High Affinity Nerve Growth Factor Receptor Market Restraints
6 Market Competitive Landscape by Players
- 6.1 Global Top High Affinity Nerve Growth Factor Receptor Players by Revenue
- 6.1.1 Global Top High Affinity Nerve Growth Factor Receptor Players by Revenue (2021-2026)
- 6.1.2 Global High Affinity Nerve Growth Factor Receptor Revenue Market Share by Players (2021-2026)
- 6.2 Global High Affinity Nerve Growth Factor Receptor Industry Players Ranking, 2023 VS 2024 VS 2025
- 6.3 Global Key Players of High Affinity Nerve Growth Factor Receptor Head Office and Area Served
- 6.4 Global High Affinity Nerve Growth Factor Receptor Players, Product Type & Application
- 6.5 Global High Affinity Nerve Growth Factor Receptor Manufacturers Established Date
- 6.6 Global High Affinity Nerve Growth Factor Receptor Market CR5 and HHI
- 6.7 Global Players Mergers & Acquisition
7 North America
- 7.1 North America High Affinity Nerve Growth Factor Receptor Market Size (2021-2032)
- 7.2 North America High Affinity Nerve Growth Factor Receptor Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 7.3 North America High Affinity Nerve Growth Factor Receptor Market Size by Country (2021-2026)
- 7.4 North America High Affinity Nerve Growth Factor Receptor Market Size by Country (2027-2032)
- 7.5 United States
- 7.5 United States
- 7.6 Canada
- 7.7 Mexico
8 Europe
- 8.1 Europe High Affinity Nerve Growth Factor Receptor Market Size (2021-2032)
- 8.2 Europe High Affinity Nerve Growth Factor Receptor Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 8.3 Europe High Affinity Nerve Growth Factor Receptor Market Size by Country (2021-2026)
- 8.4 Europe High Affinity Nerve Growth Factor Receptor Market Size by Country (2027-2032)
- 8.5 Germany
- 8.6 France
- 8.7 U.K.
- 8.8 Italy
- 8.9 Spain
- 8.10 Russia
- 8.11 Netherlands
- 8.12 Nordic Countries
9 Asia-Pacific
- 9.1 Asia-Pacific High Affinity Nerve Growth Factor Receptor Market Size (2021-2032)
- 9.2 Asia-Pacific High Affinity Nerve Growth Factor Receptor Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 9.3 Asia-Pacific High Affinity Nerve Growth Factor Receptor Market Size by Country (2021-2026)
- 9.4 Asia-Pacific High Affinity Nerve Growth Factor Receptor Market Size by Country (2027-2032)
- 9.5 China
- 9.6 Japan
- 9.7 South Korea
- 9.8 India
- 9.9 Australia
- 9.10 China Taiwan
- 9.11 Southeast Asia
10 South America
- 10.1 South America High Affinity Nerve Growth Factor Receptor Market Size (2021-2032)
- 10.2 South America High Affinity Nerve Growth Factor Receptor Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 10.3 South America High Affinity Nerve Growth Factor Receptor Market Size by Country (2021-2026)
- 10.4 South America High Affinity Nerve Growth Factor Receptor Market Size by Country (2027-2032)
- 10.5 Brazil
- 10.6 Argentina
- 10.7 Chile
- 10.8 Colombia
- 10.9 Peru
11 Middle East & Africa
- 11.1 Middle East & Africa High Affinity Nerve Growth Factor Receptor Market Size (2021-2032)
- 11.2 Middle East & Africa High Affinity Nerve Growth Factor Receptor Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 11.3 Middle East & Africa High Affinity Nerve Growth Factor Receptor Market Size by Country (2021-2026)
- 11.4 Middle East & Africa High Affinity Nerve Growth Factor Receptor Market Size by Country (2027-2032)
- 11.5 Saudi Arabia
- 11.6 Israel
- 11.7 United Arab Emirates
- 11.8 Turkey
- 11.9 Iran
- 11.10 Egypt
12 Players Profiled
- 12.1 Merck & Co Inc
- 12.1.1 Merck & Co Inc Company Information
- 12.1.2 Merck & Co Inc Business Overview
- 12.1.3 Merck & Co Inc Revenue in High Affinity Nerve Growth Factor Receptor Business (2021-2026)
- 12.1.4 Merck & Co Inc High Affinity Nerve Growth Factor Receptor Product Portfolio
- 12.1.5 Merck & Co Inc Recent Developments
- 12.2 AstraZeneca Plc
- 12.2.1 AstraZeneca Plc Company Information
- 12.2.2 AstraZeneca Plc Business Overview
- 12.2.3 AstraZeneca Plc Revenue in High Affinity Nerve Growth Factor Receptor Business (2021-2026)
- 12.2.4 AstraZeneca Plc High Affinity Nerve Growth Factor Receptor Product Portfolio
- 12.2.5 AstraZeneca Plc Recent Developments
- 12.3 Tiziana Life Sciences Plc
- 12.3.1 Tiziana Life Sciences Plc Company Information
- 12.3.2 Tiziana Life Sciences Plc Business Overview
- 12.3.3 Tiziana Life Sciences Plc Revenue in High Affinity Nerve Growth Factor Receptor Business (2021-2026)
- 12.3.4 Tiziana Life Sciences Plc High Affinity Nerve Growth Factor Receptor Product Portfolio
- 12.3.5 Tiziana Life Sciences Plc Recent Developments
- 12.4 Sienna Biopharmaceuticals Inc
- 12.4.1 Sienna Biopharmaceuticals Inc Company Information
- 12.4.2 Sienna Biopharmaceuticals Inc Business Overview
- 12.4.3 Sienna Biopharmaceuticals Inc Revenue in High Affinity Nerve Growth Factor Receptor Business (2021-2026)
- 12.4.4 Sienna Biopharmaceuticals Inc High Affinity Nerve Growth Factor Receptor Product Portfolio
- 12.4.5 Sienna Biopharmaceuticals Inc Recent Developments
- 12.5 Rottapharm Biotech Srl
- 12.5.1 Rottapharm Biotech Srl Company Information
- 12.5.2 Rottapharm Biotech Srl Business Overview
- 12.5.3 Rottapharm Biotech Srl Revenue in High Affinity Nerve Growth Factor Receptor Business (2021-2026)
- 12.5.4 Rottapharm Biotech Srl High Affinity Nerve Growth Factor Receptor Product Portfolio
- 12.5.5 Rottapharm Biotech Srl Recent Developments
- 12.6 Proximagen Ltd
- 12.6.1 Proximagen Ltd Company Information
- 12.6.2 Proximagen Ltd Business Overview
- 12.6.3 Proximagen Ltd Revenue in High Affinity Nerve Growth Factor Receptor Business (2021-2026)
- 12.6.4 Proximagen Ltd High Affinity Nerve Growth Factor Receptor Product Portfolio
- 12.6.5 Proximagen Ltd Recent Developments
- 12.7 Plexxikon Inc
- 12.7.1 Plexxikon Inc Company Information
- 12.7.2 Plexxikon Inc Business Overview
- 12.7.3 Plexxikon Inc Revenue in High Affinity Nerve Growth Factor Receptor Business (2021-2026)
- 12.7.4 Plexxikon Inc High Affinity Nerve Growth Factor Receptor Product Portfolio
- 12.7.5 Plexxikon Inc Recent Developments
- 12.8 Nerviano Medical Sciences Srl
- 12.8.1 Nerviano Medical Sciences Srl Company Information
- 12.8.2 Nerviano Medical Sciences Srl Business Overview
- 12.8.3 Nerviano Medical Sciences Srl Revenue in High Affinity Nerve Growth Factor Receptor Business (2021-2026)
- 12.8.4 Nerviano Medical Sciences Srl High Affinity Nerve Growth Factor Receptor Product Portfolio
- 12.8.5 Nerviano Medical Sciences Srl Recent Developments
- 12.9 Loxo Oncology Inc
- 12.9.1 Loxo Oncology Inc Company Information
- 12.9.2 Loxo Oncology Inc Business Overview
- 12.9.3 Loxo Oncology Inc Revenue in High Affinity Nerve Growth Factor Receptor Business (2021-2026)
- 12.9.4 Loxo Oncology Inc High Affinity Nerve Growth Factor Receptor Product Portfolio
- 12.9.5 Loxo Oncology Inc Recent Developments
- 12.10 Ignyta Inc
- 12.10.1 Ignyta Inc Company Information
- 12.10.2 Ignyta Inc Business Overview
- 12.10.3 Ignyta Inc Revenue in High Affinity Nerve Growth Factor Receptor Business (2021-2026)
- 12.10.4 Ignyta Inc High Affinity Nerve Growth Factor Receptor Product Portfolio
- 12.10.5 Ignyta Inc Recent Developments
- 12.11 Handok Inc
- 12.11.1 Handok Inc Company Information
- 12.11.2 Handok Inc Business Overview
- 12.11.3 Handok Inc Revenue in High Affinity Nerve Growth Factor Receptor Business (2021-2026)
- 12.11.4 Handok Inc High Affinity Nerve Growth Factor Receptor Product Portfolio
- 12.11.5 Handok Inc Recent Developments
- 12.12 Genzyme Corp
- 12.12.1 Genzyme Corp Company Information
- 12.12.2 Genzyme Corp Business Overview
- 12.12.3 Genzyme Corp Revenue in High Affinity Nerve Growth Factor Receptor Business (2021-2026)
- 12.12.4 Genzyme Corp High Affinity Nerve Growth Factor Receptor Product Portfolio
- 12.12.5 Genzyme Corp Recent Developments
- 12.13 Dompe Farmaceutici SpA
- 12.13.1 Dompe Farmaceutici SpA Company Information
- 12.13.2 Dompe Farmaceutici SpA Business Overview
- 12.13.3 Dompe Farmaceutici SpA Revenue in High Affinity Nerve Growth Factor Receptor Business (2021-2026)
- 12.13.4 Dompe Farmaceutici SpA High Affinity Nerve Growth Factor Receptor Product Portfolio
- 12.13.5 Dompe Farmaceutici SpA Recent Developments
- 12.14 Daiichi Sankyo Co Ltd
- 12.14.1 Daiichi Sankyo Co Ltd Company Information
- 12.14.2 Daiichi Sankyo Co Ltd Business Overview
- 12.14.3 Daiichi Sankyo Co Ltd Revenue in High Affinity Nerve Growth Factor Receptor Business (2021-2026)
- 12.14.4 Daiichi Sankyo Co Ltd High Affinity Nerve Growth Factor Receptor Product Portfolio
- 12.14.5 Daiichi Sankyo Co Ltd Recent Developments
- 12.15 Astellas Pharma Inc
- 12.15.1 Astellas Pharma Inc Company Information
- 12.15.2 Astellas Pharma Inc Business Overview
- 12.15.3 Astellas Pharma Inc Revenue in High Affinity Nerve Growth Factor Receptor Business (2021-2026)
- 12.15.4 Astellas Pharma Inc High Affinity Nerve Growth Factor Receptor Product Portfolio
- 12.15.5 Astellas Pharma Inc Recent Developments
- 12.16 Array BioPharma Inc
- 12.16.1 Array BioPharma Inc Company Information
- 12.16.2 Array BioPharma Inc Business Overview
- 12.16.3 Array BioPharma Inc Revenue in High Affinity Nerve Growth Factor Receptor Business (2021-2026)
- 12.16.4 Array BioPharma Inc High Affinity Nerve Growth Factor Receptor Product Portfolio
- 12.16.5 Array BioPharma Inc Recent Developments
13 Report Conclusion
14 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst